Refine by
Next Generation Nanopore Sequencing Articles & Analysis
145 news found
Creative Proteomics, a global leader in proteomics and bioanalytical services, has launched its state-of-the-art N-terminal Edman Degradation service, offering researchers a precise and reliable solution for protein sequence analysis. This service leverages the classic Edman Degradation method, refined with modern technology, to deliver unparalleled accuracy in determining the N-terminal ...
Next-generation sequencing (NGS) has revolutionized the field of genomics by enabling researchers to generate vast amounts of sequence data in a single experiment. This technology is particularly valuable in applications such as metagenomics, where it allows for the analysis of complex microbial communities, such as those found in the human gut. However, despite its advantages, NGS is not without ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. The two companies have expanded the integration of Genomenon’s Mastermind® Genomic ...
In this piece, we talked to the two presenters of the poster “The Validation of a Homologous Recombination Deficiency Assay into Clinical Practice within the NHS”, Elizabeth Ratsma, Pre-Registration Clinical Scientist – Cancer Genomics and Charlotte Flanagan, PhD, Innovation Lead, from The Royal Marsden NHS Foundation Trust. The poster was recently presented at the ESMO ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company’s work with biopharma company Boundless Bio. SOPHiA GENETICS first partnered with Boundless Bio in 2022 to develop and deploy Boundless Bio’s extrachromosomal DNA (ecDNA) detection algorithm as a clinical trial device, to ...
CD Genomics, a leading provider of genomic research solutions, today announced the launch of its cutting-edge Nanopore sequencing services, marking a significant advancement in DNA and RNA analysis capabilities. This innovative technology, developed by Oxford Nanopore Technologies, is set to transform the landscape of life sciences research, offering unprecedented insights into genetic material. ...
Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for all solid tumor cancers as an ...
ByTempus
CD Genomics, a leading provider of genomic services, is proud to announce a groundbreaking advancement in microsatellite development that is set to transform the landscape of genetic research. Leveraging the power of next-generation sequencing (NGS), CD Genomics enables researchers to harness the full potential of microsatellite markers for a wide range of applications. Microsatellites, also ...
As the field of genomics continues to evolve, long non-coding RNAs (lncRNAs) have emerged as a fascinating frontier, offering unprecedented insights into the complex regulatory mechanisms underlying biological processes and disease states. CD Genomics, a leading provider of high-throughput sequencing services, is at the forefront of this exciting development, empowering researchers to unlock the ...
CD Genomics, a trailblazer in genomics and epigenomics research, is proud to announce the launch of MeRIP Sequencing, a cutting-edge technology revolutionizing the analysis of m6A modifications on RNA molecules. This breakthrough method promises to provide researchers with unparalleled insights into the dynamic world of epigenetic modifications, setting a new standard in precision ...
CD Genomics, a prominent leader in the next generation sequencing arena, proudly announce the launch of a groundbreaking 5mC/5hmC sequencing service. This innovative service is poised to empower researchers by providing a deeper insight into epigenetic variations, unlocking the mysteries of epigenetics, and catalyzing pivotal advancements in the realm of life science research and precision ...
CD Genomics, an excellent leader in genomics and bioinformatics, has unveiled a groundbreaking leap forward in TCR-Seq technology, poised to revolutionize immune repertoire profiling. With an unwavering commitment to innovation and precision, CD Genomics continues to redefine the genomics research landscape. TCR-Seq, short for T Cell Receptor Sequencing, is an instrumental tool that enables ...
CD Genomics, a global leader in genomic and bioinformatics solutions, is pleased to announce the official launch of its Viral Metagenomic Sequencing service. This state-of-the-art offering represents a major advancement in the field of pathogen research and promises to provide unparalleled insights into viral communities. Viruses, being the most abundant entities on our planet, play a pivotal ...
CD Genomics, a renowned leader in genomics and next-generation sequencing (NGS) applications, has unveiled its cutting-edge HLA typing solutions, revolutionizing immune profiling and transplantation compatibility assessment. The human leukocyte antigen (HLA) system plays a crucial role in immune regulation and determining transplantation compatibility. HLA typing, the process of identifying ...
CD Genomics, a global leader in genomics solutions, has recently unveiled its highly anticipated DAP-Seq service. This cutting-edge offering promises to provide researchers worldwide with an efficient application solution for DNA affinity purification sequencing technology. With this service, the company aims to revolutionize the field of life sciences and empower researchers to unlock the ...
CD Genomics, a renowned provider of genomics services, is proud to unveil its cutting-edge Whole Exome Sequencing (WES) service. This offering provides researchers and clinicians with a powerful tool to investigate the exome, shedding light on the intricacies of the human genome and propelling our understanding of genetic diseases. In the era of precision medicine, comprehensive and precise ...
CD Genomics, a leading provider of genomic solutions, has announced a groundbreaking development in genomic research with the introduction of their Full-Length Transcripts Sequencing (Iso-Seq) technology. This innovative advancement promises to revolutionize the field, providing researchers in the life sciences with an unprecedented opportunity to gain comprehensive insights into the complexity ...
CD Genomics, a global leader in transcriptomics solutions, unveils its mature Nanopore Direct RNA Sequencing service that can propel transcriptomics research to new heights. ...
CD Genomics, a leading provider of transcriptomics sequencing solutions, is pleased to announce the launch of its Exosomal RNA Sequencing service. This innovative service is set to provide researchers with comprehensive and accurate analysis of exosomal RNA, facilitating a deeper understanding of their functional significance in various biological processes. Exosomes, small extracellular ...